Amantadine/oseltamivir/ribavirin - Adamas Pharmaceuticals

Drug Profile

Amantadine/oseltamivir/ribavirin - Adamas Pharmaceuticals

Alternative Names: ADS-8902; Amantadine/ribavirine/oseltamivir; Oseltamivir/amantadine/ribavirin; Oseltamivir/ribavirin/amantadine; Ribavirin/amantadine/oseltamivir; Ribavirin/oseltamivir/amantadine

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adamas Pharmaceuticals
  • Developer Adamas Pharmaceuticals; National Institutes of Health (USA)
  • Class Acetamides; Adamantanes; Antivirals; Cyclohexenes; Esters; Furans; Organic bridged compounds; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Dopamine receptor agonists; Ion channel modulators; Neuraminidase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype; Influenza A virus infections

Most Recent Events

  • 14 Sep 2017 Chemical structure information added
  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Canada (PO)
  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top